Business Wire

New Global GCCA Initiative to Rally Building Value Chain for Cement and Concrete Net Zero Mission

2.10.2025 16:05:00 CEST | Business Wire | Press Release

Share

The Global Cement and Concrete Association (GCCA) has launched a new initiative and category of membership - Net Zero Value Chain Partners (NZVCP) - to support and help deliver the industry’s net zero mission. With a membership that extends beyond cement and concrete manufacturers, the NZVCP initiative is for organisations in the wider building value chain, such as equipment suppliers, admixture companies, industrial infrastructure partners for carbon capture, utilization and storage, and other solutions providers, to share expertise, innovation and ideas, and key engagement to help decarbonise the industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251002030117/en/

The first six organisations to join the GCCA NZVCP

Dominik von Achten, GGCA President and Chairman of the Managing Board of Heidelberg Materials said: “Our industry is fully committed to reaching Net Zero, and we are working hard to drive progress. However, we know we cannot achieve it alone and need the support, expertise, and partnerships across our value chain. That’s why we have created a new engagement structure to work closer with organisations who are also committed to building a net-zero future.”

Value chain companies will partner with the GCCA’s 50 world leading cement and concrete producers, participating in activities, working groups, key events and programmes, and deepening collaboration across the industry to help decarbonise cement and concrete, the world’s most used material after water.

Thomas Guillot, GCCA Chief Executive said: “Concrete is seen as the essential material because it is used all across the world in buildings, houses and key infrastructure, underpinning our modern world. It makes great sense to engage more deeply with those who provide our industry equipment, services and solutions for the manufacture and use of our material.”

GCCA has already welcomed its first NZVCPs - CDE; KHD; Master Builders Solutions; Saint-Gobain; Schneider Electric; Sinoma International.

Darren Eastwood, Strategic Development Director of CDE said: “CDE is thrilled to be joining the GCCA. The transformative potential of turning underutilized and discarded materials into catalysts for decarbonization is immense for the cement and concrete industry. This is not just collaboration, the Net Zero Value Chain Partners program is a bold step towards reshaping our joint future.”

Matthias Mersmann, Chief Technology Officer of KHD said:“We highly welcome the GCCA’s approach to open the membership for value chain partners, because we know that innovation projects in the cement industry can only be successful when cement producers and technology suppliers cooperate intensely. This is even more true for solving the biggest challenge that has ever been posed to the cement industry: the transformation into the decarbonized and digitized future.”

Paul H. Seiler, Vice President of Marketing, Master Builders Solutions said:“We are very pleased to join the GCCA as a Net Zero Value Chain Partner. Master Builders Solutions is focused on developing technologies that will enable the decarbonization of our industry. This initiative is key in bringing the main stakeholders to the table and working together towards achieving this important goal. Master Builders Solutions is honored to be a partner, and we look forward to what we will accomplish together.”

Gustavo Blazquez, Specialty Construction Chemicals Business Line Director, Saint-Gobain said: “Saint-Gobain is proud to join the GCCA’s ‘Net Zero Value Chain Partners’ initiative, reinforcing our Group’s commitment to sustainable construction. Through our Chryso and Fosroc additives and admixtures, we actively contribute to reducing the carbon footprint of cement and concrete and supporting a circular economy. By engaging in this collective effort, we aim to accelerate progress across the value chain and help build a more sustainable future, in line with Saint-Gobain’s purpose: ‘Making the world a better home’.”

Maxime Ramael, Global Business Development Manager, Green Cement, Schneider Electric said: "We are proud to join the GCCA as a Net Zero Value Chain Partner. At Schneider Electric, our mission is to accelerate sustainability through innovation, combining digitalization, electrification, and advanced energy management solutions. By harnessing the power of software and Artificial Intelligence alongside our industrial expertise, we help the cement sector reimagine processes, optimize operations, and reduce emissions at scale. The road to decarbonization demands not only ambition but also collective action, and we believe technology is the catalyst that turns vision into reality.”

Dr. Sui Tongbo, VP of Sinoma International said:“We are very pleased to join the GCCA as a Net Zero Value Chain Partner. We focus on delivering cutting-edge decarbonisation total solutions for the cement industry which are essential to achieving a net zero future. These include technologies for energy efficiency improvement, alternative raw materials & fuels and new energy, clinker substitution by SCM, new low-carbon clinker cements, oxy-fuel combustion coupled with carbon capture and extended carbon mitigation technologies along industry chain. We look forward to collaborating with global partners, sharing expertise, and accelerating the transition towards a sustainable future together.”

More information at gccassociation.org/nzvcp.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251002030117/en/

Contacts

Media enquiries: Paul.adeleke@gccasociation.org

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye